Fluoxetine

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Adofen; Apo-Fluoxetine; Dom-Fluoxetine; Fluctin; Fluctine; Fludac; Fluoxac; Fluoxeren; Fluxil; Fontex; Prozac (Lilly); Sarafem (Warner Chilcott); Symbyax (Lilly)
  • INDICATIONS: Depression, obsessive-compulsive disorder
  • CLASS: Antidepressant, Selective serotonin reuptake inhibitor (SSRI)
  • HALF-LIFE: 2–3 days

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for Major Depressive Disorder (MDD) and other psychiatric disorders.
Sarafem is not approved for use in pediatric patients with MDD and obsessive compulsive disorder. Symbyax is not approved for use in children and adolescents.

Symbyax is fluoxetine and olanzapine.

SUICIDAL THOUGHTS AND BEHAVIORS

See full prescribing information for complete boxed warning.

Our database has 130 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fluoxetine in combination with olanzapine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 10/15/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top